ClinConnect ClinConnect Logo
Search / Trial NCT06536517

The Effects of One-time Intraoperative Methadone During Laparoscopic Hysterectomy in Reducing Opioid Prescription.

Launched by JOHNS HOPKINS UNIVERSITY · Jul 31, 2024

Trial Information

Current as of June 26, 2025

Recruiting

Keywords

Hysterectomy Methadone Opioids

ClinConnect Summary

This clinical trial is studying how a single dose of Methadone given during laparoscopic hysterectomy surgery can help manage pain and reduce the need for prescription opioids afterward. The aim is to find a better way to control pain after surgery, especially since there is a growing problem with opioid misuse and over-prescription in the recovery phase. Participants will either receive Methadone or standard short-acting opioids during their surgery, and the researchers hope that using Methadone will lower the amount of additional pain medication needed after the operation.

To participate in this trial, you must be at least 18 years old, have a uterus, and be scheduled for a minimally invasive hysterectomy for non-cancerous reasons. However, individuals with chronic pain conditions, those currently using long-term opioids, or those with certain medical conditions may not be eligible. If you join the study, you can expect to be closely monitored for pain management during and after your surgery, and you will be contributing to important research aimed at improving pain care while reducing reliance on opioids.

Gender

FEMALE

Eligibility criteria

  • Inclusion Criteria:
  • Individuals with a uterus
  • Age 18 years old and above
  • Undergoing minimally invasive (laparoscopic or robotic) hysterectomy with ovarian preservation
  • Benign indications for hysterectomy
  • Agreeing to participate
  • Exclusion Criteria:
  • Chronic pain syndromes patients including fibromyalgia
  • Patients currently on long-term (i.e. for more than three months) opioid use
  • Patients currently on agonist-antagonist medications (e.g. buprenorphine)
  • Patients taking a selective serotonin reuptake inhibitor or monoamine oxidase inhibitor
  • Conversion to laparotomy
  • Allergy or other contraindication to the prescribed medications such as methadone, fentanyl, acetaminophen or oxycodone
  • Severe Obstructive Sleep Apnea (OSA)
  • Pregnant/breastfeeding patients

About Johns Hopkins University

Johns Hopkins University, a prestigious research institution located in Baltimore, Maryland, is renowned for its commitment to advancing medical science and public health through innovative clinical trials. With a rich history of groundbreaking research and a multidisciplinary approach, the university's clinical trial initiatives focus on translating scientific discoveries into effective treatments and interventions. Leveraging state-of-the-art facilities and a collaborative network of experts, Johns Hopkins University conducts rigorous clinical studies that aim to improve patient outcomes and address critical health challenges. Its dedication to ethical standards and participant safety underscores its role as a leader in clinical research.

Locations

Baltimore, Maryland, United States

Baltimore, Maryland, United States

Patients applied

0 patients applied

Trial Officials

Mostafa Borahay, MD, MBA, PhD

Principal Investigator

Study Principal Investigator

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported